Boston Scientific Corp.'s Farapoint, its latest pulsed field ablation catheter, received U.S. FDA approval for use as an ...

Immunofoco Biotechnology Co. Ltd. reported encouraging early clinical data for its CLDN18.2-targeted CAR T therapy, IMC-002, in heavily pretreated gastric and gastroesophageal junction cancer, adding ...

Bacillus anthracis is a spore-forming soil bacterium that becomes metabolically active when taken up by a host, causing ...

Dispatch Biotherapeutics Inc. has obtained IND clearance from the FDA for DISP-10, enabling the initiation of a phase I study ...

Abbvie Inc. announced its agreement to focus on improving access and lowering the cost of medicines, becoming the latest pharma to fall in line with the Trump administration’s most-favored nation (MFN ...

U.S. Health and Human Services Secretary Robert Kennedy has once again expanded the CDC’s Advisory Committee on Immunization Practices (ACIP), this time adding two more ob-gyns to the membership list.

Researchers at Iama Therapeutics Srl and Italian Institute of Technology have disclosed solute carrier family 12 member 2 (SLC12A2; NKCC1) inhibitors reported to be useful for the treatment of Down ...

Illumina Inc. presented at the J.P. Morgan 2026 Healthcare Conference on Jan. 13 and introduced what it said is the world's largest genome-wide genetic perturbation dataset, being built to accelerate ...

Boston Scientific Corp. plans to acquire Valencia Technologies Corp. in the first half of 2026 in a move that will expand its urology portfolio. Valencia makes the Ecoin system, an implantable tibial ...

After raising AU$29 million (US$19.44 million) in a series A round, Rage Biotech Pty Ltd. is beginning phase I trials of its ...

Crinetics Pharmaceuticals Inc. has described drug conjugates consisting of a non-peptide moiety targeting G protein-coupled receptors (GPCRs) covalently linked to a chemotherapeutic moiety through a ...

Researchers from Stanford School of Medicine and Yonsei University College of Medicine reported the discovery and preclinical characterization of novel KLHDC2-mediated CDK6-selective degraders.